Nuclera, a BioTech firm located in Cambridge, has appointed Dr Jonathan Milner as its new non-executive chairman. The company’s eProtein Discovery benchtop system enables rapid protein prototyping, which helps pharmaceutical companies to rapidly produce high-quality, soluble, and active proteins.
The technology aims to accelerate improvements in human health. Nuclera has a team of over 100 employees, including software engineers, engineers, and scientists, in Boston, Massachusetts. Dr Milner, who founded and was the former CEO of Abcam, a BioTech company specializing in antibodies, has joined Nuclera’s board and also participated in its Series B financing round in 2021.
Nuclera has announced collaborations with AlphaFold2 from Google Cloud and AI partner DeepMirror, which it hopes will accelerate the drug discovery process by more than 20x and save companies millions of dollars annually. Dr Chen, the CEO of Nuclera, stated, “We are thrilled to have Jonathan join the Nuclera team.
He is a titan in the life sciences industry, and we are delighted to have him on board as we grow from strength to strength.” Dr Milner said, “I am delighted to join the Nuclera team as they bring the eProtein Discovery to the market.”
